Filing Flows

Filing Flows › Health Care › Integrated Biopharma (INBP)

Integrated Biopharma (INBP) earnings and revenue breakdown

Latest: Q4 FY26 · 10-K filed Sep 25, 2026 · Integrated Biopharma (INBP) Q4 FY26 earnings results →

Q4 FY26 Revenue down 31% year over year to $9.8M · 14¢ of every $1 of revenue lost · operating margin -8.9%

Integrated Biopharma made $9.8M in Q4 FY26 (-31% Y/Y): Contract Manufacturing $9.5M, Other Nutraceutical Business $318K. Operating margin -8.9%, net loss $1.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Sep 25, 2026.

Revenue$9.8M
Year over year-31%
Operating margin-8.9%
Net earnings−$1.4M
Operating cash flow−$1.2M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $9.8M in Q4 FY26, down 31% year over year and down 3% from the previous quarter. Contract Manufacturing was the largest line at 97% of revenue.

Gross margin was 0.3%, down 10.1 points from Q4 FY25. Operating costs exceeded revenue by $869K, an operating margin of -8.9%. Operating expenses grew 2% against a revenue fall of 31%. The quarter ended with a net loss of $1.4M, wider than the previous quarter's $837K loss.

Operating cash flow was −$1.2M. Non-cash charges added back $70K of depreciation and $51K of share-based compensation. Capital expenditures of $149K exceeded it, leaving free cash flow of −$1.3M.

Quarterly history

Integrated Biopharma revenue by quarterIntegrated Biopharma revenue by quarter$12.6MQ2 FY25$13.9MQ3 FY25$14.2MQ4 FY25$12.7MQ1 FY26$11.3MQ2 FY26$10.1MQ3 FY26$9.8MQ4 FY26
Integrated Biopharma net earnings by quarterIntegrated Biopharma net earnings by quarter$116KQ2 FY25$611KQ3 FY25−$178KQ4 FY25$123KQ1 FY26−$762KQ2 FY26−$837KQ3 FY26−$1.4MQ4 FY26
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q4 FY2610-KSep 25, 2026$9.8M-31%-8.9%−$1.4M−$1.2M
Q3 FY2610-QMay 8, 2026$10.1M-28%-10.7%−$837K$517K
Q2 FY2610-QFeb 11, 2026$11.3M-11%-8.1%−$762K$617K
Q1 FY2610-QNov 10, 2025$12.7M-7%1.3%$123K$1.3M
Q4 FY2510-KSep 23, 2025$14.2M+11%4.2%−$178K$591K
Q3 FY2510-QMay 14, 2025$13.9M+6%5.3%$611K$616K
Q2 FY2510-QFeb 13, 2025$12.6M+10%1.6%$116K$201K

Charts

Integrated Biopharma: revenue growth, year over year and quarter over quarterIntegrated Biopharma: revenue growth, year over year and quarter over quarterY/YQ/Q+10%Q2 FY25+6%+11%Q3 FY25+11%+2%Q4 FY25-7%-10%Q1 FY26-11%-11%Q2 FY26-28%-10%Q3 FY26-31%-3%Q4 FY26
Latest (Q4 FY26): Y/Y -31%, Q/Q -3%.
Integrated Biopharma: where the cash came from (+) and went (−), FY26Integrated Biopharma: where the cash came from (+) and went (−), FY26Operating cash flow$1.2MCash drawn (+) / kept (−)−$856KCapital spending−$346KNet borrowing (+) / repaid (−)−$45KAsset & business sales$6K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Integrated Biopharma: profit against cash, quarter by quarterIntegrated Biopharma: profit against cash, quarter by quarterNet incomeOperating cash flow$259K$657KQ1 FY25$116K$201KQ2 FY25$611K$616KQ3 FY25−$178K$591KQ4 FY25$123K$1.3MQ1 FY26−$762K$617KQ2 FY26−$837K$517KQ3 FY26−$1.4M−$1.2MQ4 FY26
Latest (Q4 FY26): Net income −$1.4M, Operating cash flow −$1.2M.
Integrated Biopharma: diluted shares by fiscal yearIntegrated Biopharma: diluted shares by fiscal year32MFY2132MFY2230MFY2331MFY2431MFY2531MFY26
-3.3% since FY21: buybacks shrank the count.
Integrated Biopharma in its industry: growth against margin (225 companies, SIC 2834)Integrated Biopharma in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMINBP (-31%, -9%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Integrated Biopharma

Integrated BioPharma, Inc. (“INBP”) is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.

In its own words, from its 8-K, filed Sep 25, 2026.

Integrated Biopharma against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -31% against the peers' median +7%. Operating margin: -8.9% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
INBP Integrated BiopharmaQ4 FY26$9.8M-31%-8.9%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Integrated Biopharma 10-K on SEC EDGAR · CIK 1016504 · Pharmaceutical Preparations

More on INBP

History

Every quarter: Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results · Q2 FY25 results

Compare INBP with

中文版：Integrated Biopharma（INBP）财报

Español · Français